# To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

> **NCT03001726** · — · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 228 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **PROCEDURE:** Gastrectomy
- **DRUG:** oxaliplatin
- **DRUG:** S1
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03001726
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2022-06
- **Final completion:** 2023-12
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001726, "To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03001726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*